We chose this PMS dataset (a combination of patients with 22q13.33 microdeletion or SHANK3 sequence variants) to evaluate specificity of the AOA2 transcriptional signature in a neurological disease with no phenotypic overlap. This evidence concerns the gene SETX and nervous system disorder.